0001209191-23-028316.txt : 20230509 0001209191-23-028316.hdr.sgml : 20230509 20230509170735 ACCESSION NUMBER: 0001209191-23-028316 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230501 FILED AS OF DATE: 20230509 DATE AS OF CHANGE: 20230509 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Howe Jolanda CENTRAL INDEX KEY: 0001974200 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38981 FILM NUMBER: 23903255 MAIL ADDRESS: STREET 1: C/O MIRUM PHARMACEUTICALS, INC. STREET 2: 950 TOWER LANE, SUITE 1050 CITY: FOSTER CITY STATE: CA ZIP: 94404 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Mirum Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001759425 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 831281555 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 950 TOWER LANE, SUITE 1050 CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 650-667-4085 MAIL ADDRESS: STREET 1: 950 TOWER LANE, SUITE 1050 CITY: FOSTER CITY STATE: CA ZIP: 94404 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2023-05-01 0 0001759425 Mirum Pharmaceuticals, Inc. MIRM 0001974200 Howe Jolanda C/O MIRUM PHARMACEUTICALS, INC. 950 TOWER LANE, SUITE 1050 FOSTER CITY CA 94404 0 1 0 0 SVP, Global Controller Common Stock 1769 D Stock Option (right to buy) 2.94 2029-03-11 Common Stock 57900 D Stock Option (right to buy) 6.27 2029-05-13 Common Stock 50000 D Stock Option (right to buy) 19.24 2030-01-09 Common Stock 25000 D Stock Option (right to buy) 19.19 2031-01-06 Common Stock 25000 D Stock Option (right to buy) 15.87 2032-01-05 Common Stock 22500 D Stock Option (right to buy) 19.98 2032-06-30 Common Stock 18750 D Stock Option (right to buy) 23.48 2033-01-30 Common Stock 21250 D Restricted Stock Units Common Stock 2500 D Restricted Stock Units Common Stock 3125 D Restricted Stock Units Common Stock 5315 D Performance Restricted Stock Units Common Tcok 1563 D 1/4th of the 62,500 shares originally subject to the option vested one year after February 28, 2019, and the balance of the shares vest in a series of 36 successive equal monthly installments at the end of each month thereafter. 1/4th of the shares vested one year after April 12, 2019 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. 1/4th of the shares vested one year after January 10, 2020 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. 1/4th of the shares vested one year after January 7, 2021 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. 1/4th of the shares vested one year after January 6, 2022 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. 1/4th of the shares vest one year after July 1, 2022 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. 1/4th of the shares vest one year after January 31, 2023 (the "Vesting Commencement Date) and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. The restricted stock units vest in a series of three successive equal annual installments beginning January 6, 2023. 1,250 shares vested January 6, 2023 and the remaining 2,500 shares vest ratably on January 6, 2024 and January 6, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). The restricted stock units vest in a series of three successive equal annual installments beginning July 1, 2023. The restricted stock units vest in a series of three successive equal annual installments beginning January 31, 2024. On March 9, 2021, the reporting person was granted performance-based restricted stock units ("PSUs"), which vest upon the satisfaction of certain performance criteria. On September 29, 2021, such performance criteria were met. 1,562 shares subject to the PSUs vested on September 29, 2021, and 1,563 shares vest on June 30, 2023. /s/ Judit Ryvkin, Attorney-in-Fact 2023-05-08 EX-24 2 poa.txt POA DOCUMENT POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Christopher Peetz and Judit Ryvkin of Mirum Pharmaceuticals, Inc. (the "Company"), signing individually, the undersigned's true and lawful attorney-in-fact and agent to: (1) execute for and on behalf of the undersigned, an officer, director or holder of 10% of more of a registered class of securities of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules thereunder; (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such forms or amendments with the United States Securities and Exchange Commission and any stock exchange or similar authority; and (3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that each of the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact or (c) until such attorney-in-fact shall no longer be employed by the Company. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 4th day of May, 2023. /s/ Jody Howe (Signature) Jody Howe (Name: Printed or Typed)